Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc. MRNS Peers
See (MRNS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MRNS | $0.55 | N/A | 30.4M | -0.22 | -$2.47 | N/A |
| VRTX | $451.52 | +1.20% | 115.9B | -117.58 | -$3.84 | N/A |
| REGN | $523.53 | +1.15% | 55.6B | 13.30 | $39.36 | +0.33% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $302.46 | -0.51% | 39.4B | -144.03 | -$2.10 | N/A |
| ARGX | $574.95 | -1.49% | 35.1B | 35.04 | $16.41 | N/A |
| BNTX | $106.89 | -1.91% | 25.7B | -29.37 | -$3.64 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| RPRX | $33.58 | +0.57% | 18.9B | 13.71 | $2.45 | +2.55% |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
MRNS vs VRTX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, VRTX has a market cap of 115.9B. Regarding current trading prices, MRNS is priced at $0.55, while VRTX trades at $451.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas VRTX's P/E ratio is -117.58. In terms of profitability, MRNS's ROE is +4.94%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, MRNS is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs REGN Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, REGN has a market cap of 55.6B. Regarding current trading prices, MRNS is priced at $0.55, while REGN trades at $523.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas REGN's P/E ratio is 13.30. In terms of profitability, MRNS's ROE is +4.94%, compared to REGN's ROE of +0.15%. Regarding short-term risk, MRNS is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs SGEN Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, MRNS is priced at $0.55, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas SGEN's P/E ratio is -57.19. In terms of profitability, MRNS's ROE is +4.94%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, MRNS is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNS.
MRNS vs ALNY Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, ALNY has a market cap of 39.4B. Regarding current trading prices, MRNS is priced at $0.55, while ALNY trades at $302.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas ALNY's P/E ratio is -144.03. In terms of profitability, MRNS's ROE is +4.94%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, MRNS is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs ARGX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, ARGX has a market cap of 35.1B. Regarding current trading prices, MRNS is priced at $0.55, while ARGX trades at $574.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas ARGX's P/E ratio is 35.04. In terms of profitability, MRNS's ROE is +4.94%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, MRNS is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs BNTX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, BNTX has a market cap of 25.7B. Regarding current trading prices, MRNS is priced at $0.55, while BNTX trades at $106.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas BNTX's P/E ratio is -29.37. In terms of profitability, MRNS's ROE is +4.94%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, MRNS is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs BGNE Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, MRNS is priced at $0.55, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas BGNE's P/E ratio is -22.55. In terms of profitability, MRNS's ROE is +4.94%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, MRNS is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs RPRX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, RPRX has a market cap of 18.9B. Regarding current trading prices, MRNS is priced at $0.55, while RPRX trades at $33.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas RPRX's P/E ratio is 13.71. In terms of profitability, MRNS's ROE is +4.94%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, MRNS is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs DNA-WT Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, MRNS is priced at $0.55, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, MRNS's ROE is +4.94%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, MRNS is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs SMMT Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, SMMT has a market cap of 16.3B. Regarding current trading prices, MRNS is priced at $0.55, while SMMT trades at $22.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas SMMT's P/E ratio is -64.94. In terms of profitability, MRNS's ROE is +4.94%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, MRNS is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs GMAB Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, GMAB has a market cap of 14.1B. Regarding current trading prices, MRNS is priced at $0.55, while GMAB trades at $22.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas GMAB's P/E ratio is 13.44. In terms of profitability, MRNS's ROE is +4.94%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, MRNS is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs INCY Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, INCY has a market cap of 13.6B. Regarding current trading prices, MRNS is priced at $0.55, while INCY trades at $70.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas INCY's P/E ratio is 350.35. In terms of profitability, MRNS's ROE is +4.94%, compared to INCY's ROE of +0.01%. Regarding short-term risk, MRNS is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs UTHR Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, UTHR has a market cap of 12.7B. Regarding current trading prices, MRNS is priced at $0.55, while UTHR trades at $281.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas UTHR's P/E ratio is 11.21. In terms of profitability, MRNS's ROE is +4.94%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, MRNS is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs KRTX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, MRNS is priced at $0.55, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas KRTX's P/E ratio is -28.09. In terms of profitability, MRNS's ROE is +4.94%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, MRNS is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNS.
MRNS vs EXEL Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, EXEL has a market cap of 11.6B. Regarding current trading prices, MRNS is priced at $0.55, while EXEL trades at $42.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas EXEL's P/E ratio is 19.42. In terms of profitability, MRNS's ROE is +4.94%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, MRNS is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs BMRN Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, BMRN has a market cap of 11B. Regarding current trading prices, MRNS is priced at $0.55, while BMRN trades at $57.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas BMRN's P/E ratio is 21.29. In terms of profitability, MRNS's ROE is +4.94%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, MRNS is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs MRNA Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, MRNA has a market cap of 10.7B. Regarding current trading prices, MRNS is priced at $0.55, while MRNA trades at $27.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas MRNA's P/E ratio is -3.17. In terms of profitability, MRNS's ROE is +4.94%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, MRNS is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs ASND Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, ASND has a market cap of 10.4B. Regarding current trading prices, MRNS is priced at $0.55, while ASND trades at $172.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas ASND's P/E ratio is -26.00. In terms of profitability, MRNS's ROE is +4.94%, compared to ASND's ROE of +1.91%. Regarding short-term risk, MRNS is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs RXDX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, MRNS is priced at $0.55, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas RXDX's P/E ratio is -56.47. In terms of profitability, MRNS's ROE is +4.94%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, MRNS is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNS.
MRNS vs IMGN Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, MRNS is priced at $0.55, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas IMGN's P/E ratio is -111.55. In terms of profitability, MRNS's ROE is +4.94%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, MRNS is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNS.
MRNS vs BPMC Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, BPMC has a market cap of 8.3B. Regarding current trading prices, MRNS is priced at $0.55, while BPMC trades at $127.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas BPMC's P/E ratio is -50.98. In terms of profitability, MRNS's ROE is +4.94%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, MRNS is less volatile compared to BPMC. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs CERE Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, MRNS is priced at $0.55, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas CERE's P/E ratio is -16.47. In terms of profitability, MRNS's ROE is +4.94%, compared to CERE's ROE of -0.43%. Regarding short-term risk, MRNS is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNS.
MRNS vs TECH Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, TECH has a market cap of 8.1B. Regarding current trading prices, MRNS is priced at $0.55, while TECH trades at $51.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas TECH's P/E ratio is 61.93. In terms of profitability, MRNS's ROE is +4.94%, compared to TECH's ROE of +0.06%. Regarding short-term risk, MRNS is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs ROIVW Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, MRNS is priced at $0.55, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, MRNS's ROE is +4.94%, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, MRNS is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs RVMD Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, RVMD has a market cap of 7.8B. Regarding current trading prices, MRNS is priced at $0.55, while RVMD trades at $41.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas RVMD's P/E ratio is -10.47. In terms of profitability, MRNS's ROE is +4.94%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, MRNS is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs ROIV Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, ROIV has a market cap of 7.7B. Regarding current trading prices, MRNS is priced at $0.55, while ROIV trades at $11.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas ROIV's P/E ratio is -15.36. In terms of profitability, MRNS's ROE is +4.94%, compared to ROIV's ROE of -0.02%. Regarding short-term risk, MRNS is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs CORT Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, CORT has a market cap of 7.7B. Regarding current trading prices, MRNS is priced at $0.55, while CORT trades at $72.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas CORT's P/E ratio is 62.84. In terms of profitability, MRNS's ROE is +4.94%, compared to CORT's ROE of +0.20%. Regarding short-term risk, MRNS is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs BBIO Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, BBIO has a market cap of 7.6B. Regarding current trading prices, MRNS is priced at $0.55, while BBIO trades at $40.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas BBIO's P/E ratio is -11.26. In terms of profitability, MRNS's ROE is +4.94%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, MRNS is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs VRNA Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, VRNA has a market cap of 7.4B. Regarding current trading prices, MRNS is priced at $0.55, while VRNA trades at $86.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas VRNA's P/E ratio is -43.39. In terms of profitability, MRNS's ROE is +4.94%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, MRNS is less volatile compared to VRNA. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs JAZZ Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, JAZZ has a market cap of 7B. Regarding current trading prices, MRNS is priced at $0.55, while JAZZ trades at $113.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas JAZZ's P/E ratio is 15.35. In terms of profitability, MRNS's ROE is +4.94%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, MRNS is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs HALO Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, HALO has a market cap of 6.6B. Regarding current trading prices, MRNS is priced at $0.55, while HALO trades at $53.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas HALO's P/E ratio is 14.30. In terms of profitability, MRNS's ROE is +4.94%, compared to HALO's ROE of +1.22%. Regarding short-term risk, MRNS is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs RETA Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, MRNS is priced at $0.55, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas RETA's P/E ratio is -66.29. In terms of profitability, MRNS's ROE is +4.94%, compared to RETA's ROE of +0.47%. Regarding short-term risk, MRNS is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for MRNS.
MRNS vs MDGL Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, MDGL has a market cap of 6.3B. Regarding current trading prices, MRNS is priced at $0.55, while MDGL trades at $282.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas MDGL's P/E ratio is -15.82. In terms of profitability, MRNS's ROE is +4.94%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, MRNS is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs TGTX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, TGTX has a market cap of 6.3B. Regarding current trading prices, MRNS is priced at $0.55, while TGTX trades at $39.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas TGTX's P/E ratio is 157.72. In terms of profitability, MRNS's ROE is +4.94%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, MRNS is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs IONS Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, IONS has a market cap of 5.9B. Regarding current trading prices, MRNS is priced at $0.55, while IONS trades at $36.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas IONS's P/E ratio is -12.32. In terms of profitability, MRNS's ROE is +4.94%, compared to IONS's ROE of -0.92%. Regarding short-term risk, MRNS is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs TLX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, TLX has a market cap of 5.8B. Regarding current trading prices, MRNS is priced at $0.55, while TLX trades at $17.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas TLX's P/E ratio is 190.89. In terms of profitability, MRNS's ROE is +4.94%, compared to TLX's ROE of +0.14%. Regarding short-term risk, MRNS is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs NUVL Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, NUVL has a market cap of 5.7B. Regarding current trading prices, MRNS is priced at $0.55, while NUVL trades at $79.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas NUVL's P/E ratio is -17.98. In terms of profitability, MRNS's ROE is +4.94%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, MRNS is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs ABCM Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, MRNS is priced at $0.55, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, MRNS's ROE is +4.94%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, MRNS is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNS.
MRNS vs ISEE Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, MRNS is priced at $0.55, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas ISEE's P/E ratio is -22.44. In terms of profitability, MRNS's ROE is +4.94%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, MRNS is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs AXSM Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, AXSM has a market cap of 5.4B. Regarding current trading prices, MRNS is priced at $0.55, while AXSM trades at $109.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas AXSM's P/E ratio is -19.05. In terms of profitability, MRNS's ROE is +4.94%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, MRNS is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs AMRN Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, AMRN has a market cap of 5.3B. Regarding current trading prices, MRNS is priced at $0.55, while AMRN trades at $12.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas AMRN's P/E ratio is -2.91. In terms of profitability, MRNS's ROE is +4.94%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, MRNS is less volatile compared to AMRN. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs ALKS Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, ALKS has a market cap of 5.1B. Regarding current trading prices, MRNS is priced at $0.55, while ALKS trades at $31.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas ALKS's P/E ratio is 14.79. In terms of profitability, MRNS's ROE is +4.94%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, MRNS is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs ADMA Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, ADMA has a market cap of 5B. Regarding current trading prices, MRNS is priced at $0.55, while ADMA trades at $20.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas ADMA's P/E ratio is 23.98. In terms of profitability, MRNS's ROE is +4.94%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, MRNS is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs PCVX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, PCVX has a market cap of 4.8B. Regarding current trading prices, MRNS is priced at $0.55, while PCVX trades at $37.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas PCVX's P/E ratio is -9.32. In terms of profitability, MRNS's ROE is +4.94%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, MRNS is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs ALPN Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, MRNS is priced at $0.55, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas ALPN's P/E ratio is -101.52. In terms of profitability, MRNS's ROE is +4.94%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, MRNS is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNS.
MRNS vs ZLAB Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, ZLAB has a market cap of 4.4B. Regarding current trading prices, MRNS is priced at $0.55, while ZLAB trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas ZLAB's P/E ratio is -16.00. In terms of profitability, MRNS's ROE is +4.94%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, MRNS is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs AKRO Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, AKRO has a market cap of 4.3B. Regarding current trading prices, MRNS is priced at $0.55, while AKRO trades at $54.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas AKRO's P/E ratio is -14.54. In terms of profitability, MRNS's ROE is +4.94%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, MRNS is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs RYTM Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, RYTM has a market cap of 4.3B. Regarding current trading prices, MRNS is priced at $0.55, while RYTM trades at $67.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas RYTM's P/E ratio is -24.06. In terms of profitability, MRNS's ROE is +4.94%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, MRNS is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs MRUS Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, MRUS has a market cap of 4.2B. Regarding current trading prices, MRNS is priced at $0.55, while MRUS trades at $56.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas MRUS's P/E ratio is -13.57. In terms of profitability, MRNS's ROE is +4.94%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, MRNS is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs OPT Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, MRNS is priced at $0.55, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas OPT's P/E ratio is -1.52. In terms of profitability, MRNS's ROE is +4.94%, compared to OPT's ROE of +2.60%. Regarding short-term risk, MRNS is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNS.
MRNS vs CYTK Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, CYTK has a market cap of 4.1B. Regarding current trading prices, MRNS is priced at $0.55, while CYTK trades at $34.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas CYTK's P/E ratio is -6.53. In terms of profitability, MRNS's ROE is +4.94%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, MRNS is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs MRTX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, MRNS is priced at $0.55, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas MRTX's P/E ratio is -4.82. In terms of profitability, MRNS's ROE is +4.94%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, MRNS is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs PTCT Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, PTCT has a market cap of 4.1B. Regarding current trading prices, MRNS is priced at $0.55, while PTCT trades at $51.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas PTCT's P/E ratio is 7.95. In terms of profitability, MRNS's ROE is +4.94%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, MRNS is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs RNA Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, RNA has a market cap of 4.1B. Regarding current trading prices, MRNS is priced at $0.55, while RNA trades at $33.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas RNA's P/E ratio is -11.21. In terms of profitability, MRNS's ROE is +4.94%, compared to RNA's ROE of -0.27%. Regarding short-term risk, MRNS is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs SLNO Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, SLNO has a market cap of 4B. Regarding current trading prices, MRNS is priced at $0.55, while SLNO trades at $79.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas SLNO's P/E ratio is -16.84. In terms of profitability, MRNS's ROE is +4.94%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, MRNS is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs KRYS Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, KRYS has a market cap of 4B. Regarding current trading prices, MRNS is priced at $0.55, while KRYS trades at $138.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas KRYS's P/E ratio is 33.22. In terms of profitability, MRNS's ROE is +4.94%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, MRNS is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs SRPT Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, SRPT has a market cap of 3.8B. Regarding current trading prices, MRNS is priced at $0.55, while SRPT trades at $39.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas SRPT's P/E ratio is -14.80. In terms of profitability, MRNS's ROE is +4.94%, compared to SRPT's ROE of -0.20%. Regarding short-term risk, MRNS is less volatile compared to SRPT. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs RYZB Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, MRNS is priced at $0.55, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas RYZB's P/E ratio is -57.86. In terms of profitability, MRNS's ROE is +4.94%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, MRNS is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for MRNS.
MRNS vs CBAY Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, MRNS is priced at $0.55, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas CBAY's P/E ratio is -32.81. In terms of profitability, MRNS's ROE is +4.94%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, MRNS is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for MRNS.
MRNS vs ACAD Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, MRNS is priced at $0.55, while ACAD trades at $22.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas ACAD's P/E ratio is 16.20. In terms of profitability, MRNS's ROE is +4.94%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, MRNS is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs CRSP Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, CRSP has a market cap of 3.7B. Regarding current trading prices, MRNS is priced at $0.55, while CRSP trades at $42.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas CRSP's P/E ratio is -9.56. In terms of profitability, MRNS's ROE is +4.94%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, MRNS is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs MTSR Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, MTSR has a market cap of 3.7B. Regarding current trading prices, MRNS is priced at $0.55, while MTSR trades at $35.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas MTSR's P/E ratio is -13.87. In terms of profitability, MRNS's ROE is +4.94%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, MRNS is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs ACLX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, ACLX has a market cap of 3.7B. Regarding current trading prices, MRNS is priced at $0.55, while ACLX trades at $66.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas ACLX's P/E ratio is -22.28. In terms of profitability, MRNS's ROE is +4.94%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, MRNS is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs RARE Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, RARE has a market cap of 3.5B. Regarding current trading prices, MRNS is priced at $0.55, while RARE trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas RARE's P/E ratio is -6.43. In terms of profitability, MRNS's ROE is +4.94%, compared to RARE's ROE of -1.86%. Regarding short-term risk, MRNS is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs SWTX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, MRNS is priced at $0.55, while SWTX trades at $46.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas SWTX's P/E ratio is -13.71. In terms of profitability, MRNS's ROE is +4.94%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, MRNS is less volatile compared to SWTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs PTGX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, PTGX has a market cap of 3.5B. Regarding current trading prices, MRNS is priced at $0.55, while PTGX trades at $56.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas PTGX's P/E ratio is 72.27. In terms of profitability, MRNS's ROE is +4.94%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, MRNS is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs LEGN Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, MRNS is priced at $0.55, while LEGN trades at $37.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas LEGN's P/E ratio is -31.90. In terms of profitability, MRNS's ROE is +4.94%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, MRNS is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs VKTX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, VKTX has a market cap of 3.3B. Regarding current trading prices, MRNS is priced at $0.55, while VKTX trades at $29.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas VKTX's P/E ratio is -25.12. In terms of profitability, MRNS's ROE is +4.94%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, MRNS is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs SRRK Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, SRRK has a market cap of 3.3B. Regarding current trading prices, MRNS is priced at $0.55, while SRRK trades at $34.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas SRRK's P/E ratio is -13.50. In terms of profitability, MRNS's ROE is +4.94%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, MRNS is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs CPRX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, CPRX has a market cap of 3.2B. Regarding current trading prices, MRNS is priced at $0.55, while CPRX trades at $26.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas CPRX's P/E ratio is 16.76. In terms of profitability, MRNS's ROE is +4.94%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, MRNS is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs KYMR Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, KYMR has a market cap of 3.2B. Regarding current trading prices, MRNS is priced at $0.55, while KYMR trades at $48.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas KYMR's P/E ratio is -15.63. In terms of profitability, MRNS's ROE is +4.94%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, MRNS is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs CRNX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, CRNX has a market cap of 3.1B. Regarding current trading prices, MRNS is priced at $0.55, while CRNX trades at $33.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas CRNX's P/E ratio is -8.71. In terms of profitability, MRNS's ROE is +4.94%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, MRNS is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs IBRX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, IBRX has a market cap of 2.9B. Regarding current trading prices, MRNS is priced at $0.55, while IBRX trades at $3.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas IBRX's P/E ratio is -5.86. In terms of profitability, MRNS's ROE is +4.94%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, MRNS is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs MLTX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, MLTX has a market cap of 2.9B. Regarding current trading prices, MRNS is priced at $0.55, while MLTX trades at $46.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas MLTX's P/E ratio is -20.03. In terms of profitability, MRNS's ROE is +4.94%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, MRNS is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs MORF Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, MRNS is priced at $0.55, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas MORF's P/E ratio is -14.88. In terms of profitability, MRNS's ROE is +4.94%, compared to MORF's ROE of -0.22%. Regarding short-term risk, MRNS is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for MRNS.
MRNS vs IMVT Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, IMVT has a market cap of 2.9B. Regarding current trading prices, MRNS is priced at $0.55, while IMVT trades at $16.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas IMVT's P/E ratio is -6.13. In terms of profitability, MRNS's ROE is +4.94%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, MRNS is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs MOR Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, MRNS is priced at $0.55, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas MOR's P/E ratio is -12.64. In terms of profitability, MRNS's ROE is +4.94%, compared to MOR's ROE of +2.51%. Regarding short-term risk, MRNS is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs KDNY Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, MRNS is priced at $0.55, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas KDNY's P/E ratio is -12.47. In terms of profitability, MRNS's ROE is +4.94%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, MRNS is less volatile compared to KDNY. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs MYOV Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, MRNS is priced at $0.55, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas MYOV's P/E ratio is -14.05. In terms of profitability, MRNS's ROE is +4.94%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, MRNS is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for MRNS.
MRNS vs AAPG Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, AAPG has a market cap of 2.6B. Regarding current trading prices, MRNS is priced at $0.55, while AAPG trades at $29.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas AAPG's P/E ratio is -40.41. In terms of profitability, MRNS's ROE is +4.94%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, MRNS is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs APGE Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, APGE has a market cap of 2.5B. Regarding current trading prices, MRNS is priced at $0.55, while APGE trades at $42.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas APGE's P/E ratio is -11.64. In terms of profitability, MRNS's ROE is +4.94%, compared to APGE's ROE of -0.19%. Regarding short-term risk, MRNS is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs NAMSW Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, NAMSW has a market cap of 2.5B. Regarding current trading prices, MRNS is priced at $0.55, while NAMSW trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas NAMSW's P/E ratio is N/A. In terms of profitability, MRNS's ROE is +4.94%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, MRNS is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs XENE Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, XENE has a market cap of 2.5B. Regarding current trading prices, MRNS is priced at $0.55, while XENE trades at $32.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas XENE's P/E ratio is -9.99. In terms of profitability, MRNS's ROE is +4.94%, compared to XENE's ROE of -0.32%. Regarding short-term risk, MRNS is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs APLS Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, APLS has a market cap of 2.5B. Regarding current trading prices, MRNS is priced at $0.55, while APLS trades at $19.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas APLS's P/E ratio is -10.88. In terms of profitability, MRNS's ROE is +4.94%, compared to APLS's ROE of -1.00%. Regarding short-term risk, MRNS is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs NAMS Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, NAMS has a market cap of 2.5B. Regarding current trading prices, MRNS is priced at $0.55, while NAMS trades at $21.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas NAMS's P/E ratio is -11.87. In terms of profitability, MRNS's ROE is +4.94%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, MRNS is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs MIRM Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, MIRM has a market cap of 2.4B. Regarding current trading prices, MRNS is priced at $0.55, while MIRM trades at $48.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas MIRM's P/E ratio is -30.42. In terms of profitability, MRNS's ROE is +4.94%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, MRNS is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs PRVB Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, MRNS is priced at $0.55, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas PRVB's P/E ratio is -16.43. In terms of profitability, MRNS's ROE is +4.94%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, MRNS is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for MRNS.
MRNS vs ARWR Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, ARWR has a market cap of 2.3B. Regarding current trading prices, MRNS is priced at $0.55, while ARWR trades at $16.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas ARWR's P/E ratio is -13.69. In terms of profitability, MRNS's ROE is +4.94%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, MRNS is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs LBPH Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, MRNS is priced at $0.55, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas LBPH's P/E ratio is -26.66. In terms of profitability, MRNS's ROE is +4.94%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, MRNS is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for MRNS.
MRNS vs BCRX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, BCRX has a market cap of 2.3B. Regarding current trading prices, MRNS is priced at $0.55, while BCRX trades at $11.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas BCRX's P/E ratio is -42.35. In terms of profitability, MRNS's ROE is +4.94%, compared to BCRX's ROE of +0.11%. Regarding short-term risk, MRNS is less volatile compared to BCRX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs VCEL Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, VCEL has a market cap of 2.3B. Regarding current trading prices, MRNS is priced at $0.55, while VCEL trades at $45.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas VCEL's P/E ratio is 914.00. In terms of profitability, MRNS's ROE is +4.94%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, MRNS is less volatile compared to VCEL. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs DICE Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, MRNS is priced at $0.55, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas DICE's P/E ratio is -21.91. In terms of profitability, MRNS's ROE is +4.94%, compared to DICE's ROE of +0.56%. Regarding short-term risk, MRNS is less volatile compared to DICE. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs DNLI Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, DNLI has a market cap of 2.2B. Regarding current trading prices, MRNS is priced at $0.55, while DNLI trades at $15.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas DNLI's P/E ratio is -5.72. In terms of profitability, MRNS's ROE is +4.94%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, MRNS is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs LGND Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, LGND has a market cap of 2.2B. Regarding current trading prices, MRNS is priced at $0.55, while LGND trades at $113.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas LGND's P/E ratio is -15.56. In terms of profitability, MRNS's ROE is +4.94%, compared to LGND's ROE of -0.16%. Regarding short-term risk, MRNS is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs VCYT Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, VCYT has a market cap of 2.2B. Regarding current trading prices, MRNS is priced at $0.55, while VCYT trades at $27.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas VCYT's P/E ratio is 66.38. In terms of profitability, MRNS's ROE is +4.94%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, MRNS is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs RXRX Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, RXRX has a market cap of 2.2B. Regarding current trading prices, MRNS is priced at $0.55, while RXRX trades at $5.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas RXRX's P/E ratio is -3.03. In terms of profitability, MRNS's ROE is +4.94%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, MRNS is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs KNSA Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, KNSA has a market cap of 2.2B. Regarding current trading prices, MRNS is priced at $0.55, while KNSA trades at $29.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas KNSA's P/E ratio is -124.04. In terms of profitability, MRNS's ROE is +4.94%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, MRNS is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs CALT Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, MRNS is priced at $0.55, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas CALT's P/E ratio is -22.73. In terms of profitability, MRNS's ROE is +4.94%, compared to CALT's ROE of -1.67%. Regarding short-term risk, MRNS is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.
MRNS vs CGON Comparison
MRNS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNS stands at 30.4M. In comparison, CGON has a market cap of 2.1B. Regarding current trading prices, MRNS is priced at $0.55, while CGON trades at $27.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNS currently has a P/E ratio of -0.22, whereas CGON's P/E ratio is -18.32. In terms of profitability, MRNS's ROE is +4.94%, compared to CGON's ROE of -0.17%. Regarding short-term risk, MRNS is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for MRNS.